The Past, Present, and Future of the Center for Tobacco Products
Register today to join us!
Featuring
[Moderator] Mazen Saleh, Senior Policy Director, Integrated Harm Reduction, R Street Institute
Matt Holman, Vice President and Chief Scientific and Regulatory Strategy Officer, Philip Morris International; Former Director, Office of Science, Center for Tobacco Products
Roxana Weil, Chief Regulatory Science Officer, McKinney Specialty Labs; Former Senior Director, Product Integrity and Toxicology, Juul; Former Lead Toxicologist, Center for Tobacco Products
Overview
The Family Smoking Prevention and Tobacco Control Act of 2009 codified the establishment of the Food and Drug Administration’s Center for Tobacco Products (CTP), with a mission to protect Americans from tobacco-related death and disease by regulating tobacco products, educating the public on the dangers of tobacco use, and promoting strategies to ensure healthier lives. After 15 years and roughly $8 billion in spending, the number of tobacco-related deaths annually has increased from approximately 423,000 in 2009 to 449,000 in 2024, which begs the question: Why?
With only a handful of reduced-risk products like e-cigarettes receiving market authorization, a booming illicit market, and an ever-growing list of lawsuits, it’s time to discuss whether the CTP is helping or hindering modern tobacco control.
Join us for a conversation with industry leaders to reflect on the progress of the CTP’s original mission and the contemporary state of tobacco control. Is there a better path forward, or is it time to cut our losses and rethink how tobacco and nicotine products are regulated in the United States?